Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANEE MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760411326
CMS profile
170140
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,617.99

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,935.00 1
Food and Beverage $529.28 12
Travel and Lodging $153.71 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANEE MEHRA

NPI 1760411326 · CMS profile ID 170140

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1760411326?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $2,617.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $24.3810/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141584750 CMS
Galvanize Therapeutics, Inc $87.9510/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144504532 CMS
AstraZeneca Pharmaceuticals LP $31.3210/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104237645 CMS
Merck Sharp & Dohme LLC $21.6107/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141953293 CMS
AstraZeneca Pharmaceuticals LP $22.1206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104222507 CMS
Novartis Pharmaceuticals Corporation $24.4105/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087148818 CMS
Daiichi Sankyo Inc. $1,935.0003/27/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455800 CMS
AstraZeneca Pharmaceuticals LP $26.5603/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105579796 CMS
Exelixis Inc. $25.0501/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138564308 CMS
EMD Serono, Inc. $25.0901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246075 CMS
EMD Serono, Inc. $71.7801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246119 CMS
EMD Serono, Inc. $45.6101/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246159 CMS
EMD Serono, Inc. $153.7101/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246127 CMS
EMD Serono, Inc. $123.4001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246149 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,242.50 5
PY2022 $4,211.09 5
PY2023 $917.82 20
PY2024 $2,617.99 14
PY2025 $273.81 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,124,333.75 93
PY2024 Principal investigator $813,892.28 61
PY2023 Principal investigator $633,471.41 125
PY2022 Principal investigator $830,697.81 139
PY2021 Recipient $330.00 1
PY2021 Principal investigator $979,164.73 91
PY2020 Principal investigator $622,730.93 67
PY2019 Principal investigator $214,554.45 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $2,256.64 12/23/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733445417
Principal investigator 1 Merck Sharp & Dohme Corporation $2,768.94 12/18/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829559
Principal investigator 1 Merck Sharp & Dohme Corporation $752.98 12/18/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829731
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 12/18/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830433
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 12/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755289
Principal investigator 1 Merck Sharp & Dohme Corporation $14,110.00 12/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829557
Principal investigator 1 Merck Sharp & Dohme Corporation $3,286.80 11/24/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755285
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829733
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829735
Principal investigator 1 Merck Sharp & Dohme Corporation $62.25 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829737
Principal investigator 1 Merck Sharp & Dohme Corporation $62.25 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829739
Principal investigator 1 Merck Sharp & Dohme Corporation $63.00 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829907
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829909
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829911
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829913
Principal investigator 1 Merck Sharp & Dohme Corporation $8.55 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740829915
Principal investigator 1 Merck Sharp & Dohme Corporation $8.85 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830081
Principal investigator 1 Merck Sharp & Dohme Corporation $1.95 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830083
Principal investigator 1 Merck Sharp & Dohme Corporation $136.00 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830085
Principal investigator 1 Merck Sharp & Dohme Corporation $15.64 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830087
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830089
Principal investigator 1 Merck Sharp & Dohme Corporation $195.20 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830257
Principal investigator 1 Merck Sharp & Dohme Corporation $20.75 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830259
Principal investigator 1 Merck Sharp & Dohme Corporation $271.17 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830261
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830263
Principal investigator 1 Merck Sharp & Dohme Corporation $22.44 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830265
Principal investigator 1 Merck Sharp & Dohme Corporation $253.23 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830427
Principal investigator 1 Merck Sharp & Dohme Corporation $76.00 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830429
Principal investigator 1 Merck Sharp & Dohme Corporation $32.55 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830431
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 11/09/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740830435
Principal investigator 1 Merck Sharp & Dohme Corporation $4,400.00 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755243
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 10/28/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755287
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755205
Principal investigator 1 Seagen Inc. $28,165.75 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733445419
Principal investigator 1 Innate Pharma, Inc $50,196.51 10/09/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615873
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755291
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755293
Principal investigator 1 Merck Sharp & Dohme Corporation $43.20 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755295
Principal investigator 1 Merck Sharp & Dohme Corporation $7.08 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755331
Principal investigator 1 Merck Sharp & Dohme Corporation $132.12 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755333
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755335
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755337
Principal investigator 1 Merck Sharp & Dohme Corporation $24.00 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755339
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755341
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755375
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755377
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755379
Principal investigator 1 Merck Sharp & Dohme Corporation $141.48 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755381
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755383
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755385
Principal investigator 1 Merck Sharp & Dohme Corporation $407.40 10/08/2020 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 740825199
Principal investigator 1 Merck Sharp & Dohme Corporation $29,172.24 09/27/2020 Non-covered Recipient Entity
U OF MARYLAND
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 740778111
Principal investigator 1 AstraZeneca UK Limited $15,840.50 09/22/2020 Non-covered Recipient Entity
University Of Maryland Baltimore
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 736743665
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755245
Principal investigator 1 Innate Pharma, Inc $1,000.00 07/31/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615871
Principal investigator 1 Innate Pharma, Inc $585.00 06/05/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615869
Principal investigator 1 Innate Pharma, Inc $49,092.03 06/01/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615867
Principal investigator 1 Merck Sharp & Dohme Corporation $6,513.99 05/08/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755249
Principal investigator 1 Merck Sharp & Dohme Corporation $38,896.32 04/16/2020 Non-covered Recipient Entity
U OF MARYLAND
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 740778109
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 04/14/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 740755247
Principal investigator 1 Innate Pharma, Inc $1,170.00 04/03/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615865
Principal investigator 1 Merck Sharp & Dohme Corporation $221,730.31 03/11/2020 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 740782845
Principal investigator 1 Innate Pharma, Inc $6,400.00 02/14/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615861
Principal investigator 1 Innate Pharma, Inc $48,819.42 02/14/2020 Non-covered Recipient Entity
University of Maryland, Baltimore
Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 714615863
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,000.00 02/14/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A MULTI CENTER OPEN LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF COMBINATION CERITINIB LDK378 AND NIVOLUMAB IN ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE ALK POSITIVE NON SMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 721487599
Principal investigator 1 PFIZER INC. $1,968.00 02/03/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
PHASE 2 OPENLABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF02341066 IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER NSCLC HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAPLASTIC LYMPHOMA KINASE ALK GENE LOCUS No dispute reported 06/30/2026 742972533
Principal investigator 1 PFIZER INC. $11,349.53 01/21/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
PHASE 2 OPENLABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF02341066 IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER NSCLC HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAPLASTIC LYMPHOMA KINASE ALK GENE LOCUS No dispute reported 06/30/2026 742969257